

LRIBUNE DE GENEVE

INTERDIT PAR LE CONSEIL D'ÉTAT VAUDOIS

MORT AU VACHERIN



Nouveau coup dur pour le vacherin Mont-d'Or: ce fromage fabriqué dans le Jura vaudois doit être immédiatement retiré du marché et ne plus être exporté parce que sa croûte peut être infectée par une bactérie responsable de la listériose. Ainsi en a décidé vendredi l'Office

fédéral de la santé publique (OFSP). Le Conseil d'Etat vaudois quant à lui a interdit avec effet immédiat la fabrication et la commercialisation du Mont-d'Or après avoir constaté une recrudescence de cas de listériose humaine dans le canton. Cette maladie provoque le décès de plu-

sieurs personnes chaque année en Suisse depuis 1983. Dix cas, dont trois mortels, ont été recensés dans le canton de Vaud depuis la mi-octobre, date à laquelle une nouvelle épidémie s'est propagée.



**Pommersche
Gutsleberwurst**

fein und grob,
je 100 g

2²⁸
€ 1,17



**Bauernsalami
"Hausmacherqualität"**

1-kg-SB-Packung

9⁹⁸
€ 5,10




Frisches Lachsfilet

Eine Spezialität zum Braten
oder Pochieren, 100 g

1⁹⁸
€ 1,01






Frequency of contamination with *Listeria* of various food items (not all isolates belong to pathogenic species)^a

Specimen	Frequency
Raw milk	1–5%
Cheese (soft)	10–20%
Meat (beef, pork): raw	≤50%
ready to eat	1–3%
Sausage (salami, mettwurst)	≤80%
Pâté	≤50%
Poultry	≤60%
Seafood	≤20%
Mushroom	10%
Lettuce	10–20%
Radish	20–30%
Carrot	0%
Tomato	0%


^aData taken from Ref. 4

pH-stability of L. monocytogenes.

Survival rate 1 hour after inoculation of Na-barbital acetate buffer








Behavior of L. monocytogenes Brie-1 in raw whole egg, albumen, and egg yolk at 20°C





The survival of *Listeria monocytogenes* strain LM 82 in a carrot macerate at 4°C (●, ○, —) or 30°C (▲, △, ---). Numbers of listerias were determined on Oxford agar (closed symbols) and on tryptose agar + streptomycin (open symbols)

Food safety

List of food items which may contain *L. monocytogenes*

- Sausages (Salami, Paté)
- Raw meat, in particular turkey and chicken
- Sandwiches
- Lettuce, raw mushrooms
- Raw milk and products made from this material (i.e. mayonnaise)
- Soft cheese (Munster, Roquefort, Camembert, Brie)
- Fresh cheese (ricotta, feta)
- Sea food (mussels, salmon)
- All kind of meals which are conserved after having been heated

List of food items which in general are free of Listeriae

- all kinds of food immediately after heating
- pasteurized milk, yoghurt (industrial products!)
- hard cheese
- chocolate, marmalade, cookies
- raw carrots
- raw apples
- raw tomatoes

Dietary Recommendations for Preventing Food-Borne Listeriosis

For all persons:

- Thoroughly cook raw food from animal sources (e.g., beef, pork, and poultry).
- Thoroughly wash raw vegetables before eating.
- Keep uncooked meats separate from vegetables, cooked foods, and ready-to-eat foods.
- Avoid consumption of raw (unpasteurized) milk or foods made from raw milk.
- Wash hands, knives, and cutting boards after handling uncooked foods.

Additional recommendations for persons at high risk (those immunocompromised by illness or medications, pregnant women, and the elderly):

- Avoid soft cheeses (e.g., Mexican-style, feta, Brie, Camembert, and blue-veined cheese). (There is no need to avoid hard cheeses, cream cheese, cottage cheese, or yogurt.)
- Leftover foods or ready-to-eat foods (e.g., hot dogs) should be reheated until steaming hot before eating.
- Although the risk for listeriosis associated with foods from delicatessen counters is relatively low, pregnant women and immunosuppressed persons may choose to avoid these foods or to thoroughly reheat cold cuts before eating.

People at risk (YOPI)

Young



Old



Pregnant





Immuno-
compro-
mised





Incidence of listeriosis in certain populations at risk (per 100,000 individuals a year)

Normal population	0.7
Aged persons (> 70 years)	2
Alcoholics	5
Diabetic people	5
Iron overload	5
Pregnant women	12
Cancer patients	15
Steroid therapy	20
Lupus erythematoses	50
Kidney transplant recipient	100
Chronic lymphatic leukemia (CLL)	200
AIDS	600
Leukemia (AML+ALL)	1,000









rep-PCR profiles obtained with primers REP 1R-I and REP 2-I.

Lanes: M = Kb DNA Ladder,

1 = *L. monocytogenes* EGD,

3 = *L. monocytogenes* 34562,


5 = *L. monocytogenes* 34564,


2 = *L. monocytogenes* NCTC 7973,

4 = *L. monocytogenes* 34563,

6 = negative control (H₂O)









Gemeldete bakterielle Meningitis in den neuen Bundesländern und Berlin 1992–1997: Letalität (auf der Basis 343 gemeldeter Sterbefälle)











Differenzierung von Arten der Gattung *Listeria*





Taxonomic relatedness of the *Listeria* species based on 16S ribosomal RNA sequence data (adapted from Collins *et al.*, 1991).

Occurrence of *Listeria* species.

	<i>L monocytogenes</i>	<i>L ivanovii</i>	<i>L innocua</i>	<i>L seeligeri</i>	<i>L welshimeri</i>
Human listeriosis cases	+	+		(+)	
Animal listeriosis cases	+	+			
Human healthy carriers	+	+	+	(+)	(+)
Animal healthy carriers	+	+	+	+	+
Food	+	+	+	+	+
Environment	+	+	+	+	+

(+): 1 strain

+ : 2 - 10 strains

++ : 11 - 50 strains

+++ : more than 50 strains

Serovare von *Listeria monocytogenes*

(nach SEELIGER, 1977, unveröffentlicht)

Bezeichnung	O - Antigene	H - Antigene
1/2 a	I II (III)	AB
1/2 b	I II (III)	ABC
1/2 c	I II (III)	B D
3 a	II (III) IV	AB
3 b	II (III) IV	ABC
3 c	II (III) IV	B D
4 a	(III) (V) VII IX	ABC
4 a b	(III) V VI VII IX	ABC
4 b	(III) V VI	ABC
4 c	(III) V VII	ABC
4 d	(III) (V) VI VIII	ABC
4 e	(III) V VI (VIII)(IX)	ABC
5	(III) (V) VI VIII X	ABC
7 ?	(III) XII XIII	ABC
Listeria spec.*	6 a (4 f) (III) V VI VII IX XV	ABC
	6 b (4 g) (III) V VI VII IX X XI	ABC

* nicht haemolysierende Stämme ; weitere Antigenkombinationen sind bekannt, aber nicht aufgeführt.

Serovar distribution in *Listeria* species.

Serovars	<i>L. monocytogenes</i>	<i>L. seeligeri</i>	<i>L. welshimeri</i>	<i>L. innocua</i>	<i>L. ivanovii</i>
1/2a,b,c	+++	+++	+		
3a,b,c	++	++			
4a,ab,b,c,d,e	+++	+	+	+	
6a,b,U.S.		++	++	+++	
5					+++


+ : 1 to 10 strains

++ : 11 to 50 strains


+++ : more than 50 strains


U.S. : undesignated serovars

General organisation of the cell wall of strains of *Listeria* showing the possible arrangements of polymers





nach Fiedler 1988











Stages in the entry, growth, movement, and spread of *Listeria* from one macrophage to another. Photographs illustrating all these intermediate stages have been presented in the figures.

nach 30 min

nach 3 h

Actin




ActA




Aktinwolke

Aktinschweif

Modell einer "Polarisierung" des aktiven ActA im Zytoplasma der Wirtszelle. Das aktive ActA ist hier rot dargestellt, in einer frühen Phase ("Aktinwolke") findet es sich auf der ganzen bakteriellen Oberfläche. Später wird es größtenteils durch Phosphorylierungen inaktiviert (hier orange wiedergegeben), so daß die aktive Form nur noch an dem bakteriellen Pol anzutreffen ist, an dem sich auch der Aktinschweif formiert.





Schematische Darstellung der Funktion des ActA-Proteins. Die vier Prolin-reichen VASP-Bindungsstellen und das N-terminal gelegene Motiv sind durch entsprechende Färbungen im ActA-Molekül angedeutet.




Directional actin assembly by *L. monocytogenes*, with filamentous actin assembled at one bacterial extremity. Shown is a double immunofluorescence confocal laser scanning micrograph of a Vero cell infected for 5 h and treated with anti-*L. monocytogenes* antiserum (bacterium; red) and fluorescein isothiocyanate-phalloidin (F-actin; green). (Reprinted with permission from *Molecular Microbiology*, vol. 13, no. 3, 1994, front cover.)


L. monocytogenes Cell-to-Cell Spread







Schematic representation of the genes and gene products of *L. monocytogenes*.











$0.1 \text{ LD}_{50} = 10^3 \text{ } L.\text{monocytogenes}$


















Hierarchy of T cell epitopes in CB6 mice



Antimicrobial activities of natural compounds against *Listeria monocytogenes*

Allyl isothiocyanate from diverse plants (Lin et al., J.Food Protect. 63, 2000, 727)

Herb extracts (Prototeca one and two) (Cutter, J.Food Protect. 63, 2000, 601)

Eucalyptus and other oils (Harkenthalet al., Pharamazie 54, 1999, 460)

Sulfur compounds from cabbage (Kyung and Fleming, J. Food Protect. 60, 1997, 67)

Furocoumarins from parsley (Manderfield et al., J. Food Protect. 60, 1997, 72)

Essential oils from plants (Aureli et al., J. Food Protect. 55, 1992, 344)

Alan P. Johnson^{*1}, James McLauchlin², Saroj Shah² and Marina Warner¹

In vitro activity of 10 antimicrobial agents against strains of *Listeria* from 515 cases of human listeriosis in the UK.

Antimicrobial agent	MIC range (mg/l)	MIC ₅₀ (mg/l)	MIC ₉₀ (mg/l)
Ampicillin	0.25-2	0.5	0.5
Penicillin	0.12-1	0.5	1
Chloramphenicol	≤2-8	8	8
Ciprofloxacin	≤0.5-8	2	4
Erythromycin	≤0.25	≤0.25	≤0.25
Gentamicin	≤2-16	≤2	4
Rifampicin	≤0.25	≤0.25	≤0.25
Tetracycline	≤0.5-256	2	4
Trimethoprim	≤0.5-1	≤0.5	≤0.5
Vancomycin	1-4	2	2

In vitro susceptibilities of 82 *Listeria monocytogenes* strains to 22 antimicrobial agents.

Antimicrobial agents	Range ($\mu\text{g/ml}$)	MIC ($\mu\text{g/ml}$)	
		50%	90%
Ampicillin	0.12-1	0.5	1
Gentamicin	\leq 0.25-0.5	\leq 0.25	\leq 0.25
Rifampin	\leq 0.008-0.06	\leq 0.008	0.03
Chloramphenicol	4-16	8	8
Tetracycline	0.12-32	0.5	1
Co-trimoxazole	\leq 0.03-0.06	\leq 0.03	0.06
Imipenem	0.03-0.12	0.06	0.06
Meropenem	0.06-0.12	0.12	0.12
Erythromycin	0.06-0.25	0.06	0.12
Azitromycin	0.5-1	1	1
Ciprofloxacin	0.5-2	1	1
Ofloxacin	2-4	4	4
Levofloxacin	0.5-2	1	1
Sparfloxacin	0.5-2	2	2
Grepafloxacin	0.25-1	0.5	1
Trovaflaxacin	0.12-0.5	0.25	0.5
Moxifloxacin	0.12-1	0.25	0.5
Gemifloxacin	0.06-0.25	0.12	0.25
Clinafloxacin	0.06-0.25	0.12	0.12
Vancomycin	1-2	1	1
Teicoplanin	0.12-0.5	0.25	0.5
Linezolid	1-1.5	1.5	1.5


In vitro susceptibility of Listeria monocytogenes to various antibiotics

agent	range of MIC values (mg/l)	interpretation of inhibitory action		
		susceptibel	intermediate	resistant
penicillin	0.06-2	•		
ampicillin/ amoxycillin	0.06-0.5	•		
azlodillin	0.5-2	•		
cephalotin	0.25-16		•	
cefotaxime	4->128			•
cefepime	4->64			•
imipenem	0.03-0.12	•		
gentamicin	0.06-4	•		
sisomicin	0.01-0.12	•		
netilmicin	0.06-32	•		
amikacin	<0.06-32	•		
kanamycin	0.5-2		•	
streptomycin	0.5-4		•	
nalidixic acid	>128			•
D-ofloxacin	>64			•
levofloxacin	1-4		•	
ciprofloxacin	0.5-2		•	
CI 934	0.25-1	•		
Bay Y 3118	0.06-0.25	•		
vancomycin	0.12-0.5	•		
teicoplanin	0.12-0.5	•		
daptomycin	0.25-4		•	
cotrimoxazole	0.06-0.5	•		
chloramphenicol	2-8		•	
rifampicin	0.04-0.25	•		
fosfomycin	4-2048			•
clindamycin	0.25-4		•	
tetracycline	0.12-0.5	•		

DNA gyrase

		10	20	30	40	50	
GyrA L. mono	1	-----SUI	VARALPDURD	GLKPUHRAIL	-50		
GyrA B. subt	1	MSEQNTPQVR	EINISQEMAT	SFLDYAMSUI	USRALPDURD	GLKPUHRAIL	50
GyrA S. pneu	1	-----	-----	-----	-----	RAIL	50
GyrA S. aure	1	MAELPQSRIN	ERNITSEMR	SFLDYAMSUI	VARALPDURD	GLKPUHRAIL	50
GyrA E. coli	1	MSDLAR-EIT	PVNIEEELKS	SYLDYAMSUI	UGRALPDURD	GLKPUHRAIL	50
		60	70	80	90	100	
GyrA L. mono	51	YAMNDLGMTS	DKAYKK3ARI	UGEVI GKYHP	HGDTAVYFTM	JRMAQDFSVR	100
GyrA B. subt	51	YAMNDLGMTS	DKPYKK3ARI	UGEVI GKYHP	HGDSAUVESM	JRMAQDFNYR	100
GyrA S. pneu	51	YGMNELGUTP	DKPHKK3ARI	TGDUMGKYHP	HGDSSTVEAM	JRMAQDWSVR	100
GyrA S. aure	51	YGLNEQGMP	DKSYKK3ARI	UGDUMGKYHP	HGDSSTVEAM	JRMAQDFSVR	100
GyrA E. coli	51	YAMNVLGNOW	NKAYKK3ARV	UGDVI GKYHP	HGDSAUVDTI	JRMAQPFSLR	100
		110	120	130	140	150	
GyrA L. mono	101	NMLVDGHGNF	GSVDGD1AAA	MRYTEARMSK	ISMELLRDIN	KDTIDYADNY	150
GyrA B. subt	101	NMLVDGHGNF	GSVDGD3AAA	MRYTEARMSK	ISMEILADIT	KDTIDYQDNY	150
GyrA S. pneu	101	NMLVDGHGNF	GSMDGD3AAA	QRYTEARMSK	IALEM1LRDIN	KNTVDFVDNY	150
GyrA S. aure	101	NMLVDGGGNF	GSMDGD3AAA	MRYTEARMTK	ITLELLRDIN	KDTIDFIDNY	150
GyrA E. coli	101	NMLVDGGGNF	GSIDGD3AAA	MRYTEI1LAK	IAHELMADLE	KETVDFVDNY	150
		160	170	180	190	200	
GyrA L. mono	151	DGSEREPUII	PARFPNLLUN	GSTGISAG--	-----	-----	200
GyrA B. subt	151	DGSEREPUMI	PSRFPNLLUN	GAAS1AUGMA	TNIPPHQLGE	IIDGULAVSE	200
GyrA S. pneu	151	DANEREPUL	PARFPNLLUN	GAT-----	-----	-----	200
GyrA S. aure	151	DGNEREPSUL	PARFPNLLAN	GASG1AUGMA	TNIPPHNLTE	LINGULSLSK	200
GyrA E. coli	151	DGTEKIPDUM	PTKIPNLLUN	GSSG1AUGMA	TNIPPHNLTE	VINGCLAYID	200

Alignment of the quinolone resistance-determining regions (QRDRs) located in the N-termini of GyrA (subunit A of DNA gyrase)



Structural alignment between GyrA of *E. coli* and of *L. monocytogenes* displaying the important amino acid variations. A section of the QRDRs near the active site Tyr122 (blue) is shown. Differences in the sidechains at the mutational hot spots Ser83 and Asp87 (*E. coli*) are coloured green and red, respectively. In this view, the additional methyl group of threonine is pointing to the right, as does the aromatic ring of phenylalanine. The altered sidechain at position 116 is marked in yellow.

DNA topoisomerase IV


		10	20	30	40	50	
ParC L. mono	1	-----	-----	-----	RALPDVADGL	KPVQRRILFA	50
ParC B. subt	1	MSQPELFHDL	PLEEVI GDRF	GRYSKYI IQD	RALPDVADGL	KPVQRRILYA	50
ParC S. pneu	1	MSN---IQNM	SLEDIMGERF	GRYSKYI IQD	RALPDVADGL	KPVQRRILYS	50
Gr1A S. aure	1	MS--EIIQDL	SLEDV GDRF	GRYSKYI IQE	RALPDVADGL	KPVQRRILYA	50
ParC E. coli	1	M-----	-----	-----	RALPFIADGL	KPVQRRILYA	50
		60	70	80	90	100	
ParC L. mono	51	MNVEGNTAEK	GFRKSAKTUG	NUIGNYHPHG	DSSUYEAMUR	MSQDWKURNM	100
ParC B. subt	51	MHTDGNTFDK	NFRKFAKTUG	NUIGNYHPHG	DSSUYEAMUR	MSQDWKURNV	100
ParC S. pneu	51	MNKDSNTFDK	SYRKSASUG	NIMGNFHPHG	DSSIYDAMUR	MSQNKKNREI	100
Gr1A S. aure	51	MYSSGNTHDK	NFRKSAKTUG	DVIGDYHPHG	DSSUYEAMUR	LSQDWKL RHV	100
ParC E. coli	51	MSELGLNBSA	KFKKSARTUG	DVLGKYHPHG	DSACYEAMUL	MAQPFSSYP	100
		110	120	130	140	150	
ParC L. mono	101	LIEMHGNNGS	VDGDP--AM	RYTEARLSPI	SAELLRDIEK	ETVDFIPNFD	150
ParC B. subt	101	LIEMHGNNGS	IDGDP--AM	RYTEARLSPI	AEELLRDIDK	NTVEFVPNFD	150
ParC S. pneu	101	LIEMHGNNGS	MDGDP--AM	RYTEARLSEI	AGYLLDIDIEK	KTVPFAWNFD	150
Gr1A S. aure	101	LIEMHGNNGS	IDNDPP--AM	RYTEAKLSL	AEELLRDINK	ETUSFIPNYD	150
ParC E. coli	101	LVDGQGNWGA	PDDPKSFAM	RYTESRLSKY	SELLSELGQ	GTADWVPNFD	150
		160	170	180	190	200	
ParC L. mono	151	DTSSSEPTULP	ARFPNLLUNG	STGISAGY--	-----	-----	200
ParC B. subt	151	DTSKPEVULP	ARFPNLLUNG	STGISAGYAT	DIPPHHLGEV	IDAVIKRIQM	200
ParC S. pneu	151	DTEKEPTULP	ARFPNLLUNG	STGISAGYAT	DIPPHNLAEV	IDAAVYMIDH	200
Gr1A S. aure	151	DTTLEPMULP	SARFPNLLUNG	STGISAGYAT	DIPPHNLAEV	IQATLKVIDN	200
ParC E. coli	151	GTLDQEPKMLP	ARLPNILLNG	TTGIAVGMAT	DIPPHNLREV	AQAATALIDQ	200

Alignment of the quinolone resistance-determining regions (QRDRs) located in the N-termini of ParC (subunit A of DNA topoisomerase IV)

**Susceptibility of *L. monocytogenes* to cephalosporins
and few other β -lactams
(MIC values: mg/l)**

SLCC 5835 (EGD) SLCC 7140 SLCC 4949

Ampicillin	0.5	2	0.5
Cephalothin	4	4	0.25
Cefoxitin	32	64	2
Cefuroxime	128	128	0.5
Cefotaxime	64	128	0.25
Cefepime	64	128	8
Cefpirome	32	64	1
Mecillinam	64	128	8
Aztreonam	>2048	>2048	4



Penicillin-binding protein (PBP) profiles of five *Listeria* species. Membranes were incubated with [3 H]-propionyl ampicillin and prepared for SDS-PAGE as described in the text. The PBPs of *L. monocytogenes* are schematically indicated on the left, with the arrow marking the position of PBP

Numbers of

Penicillin

Binding

Proteins

from *Listeria monocytogenes*
per cell

PBP 1 : 120

PBP 2 : 80


PBP 3 : 145

PBP 4 : 130

PBP 5 : 600

PBP 3 of *Listeria* ssp.

- **identical in all *Listeria* ssp.**
- **involved in the last stages of peptidoglycan synthesis**
- **essential (blockage of this enzyme has deleterious consequences for the bacterial cell)**
- **does not bind cefotaxime**
- **does not bind aztreonam**



agent	range of MIC values (mg/l)	interpretation of inhibitory action			interpretation of bactericidal action		
		susceptibel	intermediate	resistant	yes	tolerant or weak	no
penicillin	0.06-2	●				●	
ampicillin/ amoxycillin	0.06-0.5	●				●	
azlocillin	0.5-2	●				●	
cephalotin	0.25-16		●				●
cefotaxime	4->128			●			●
cefepime	4->64			●			●
imipenem	0.03-0.12	●				●	
gentamicin	0.06-4	●			●		
sisomicin	0.01-0.12	●			●		
netilmicin	0.06-32	●			●		
amikacin	<0.06-32	●			●		
kanamycin	0.5-2		●			●	
streptomycin	0.5-4		●			●	
nalidixic acid	>128			●			●
D-ofloxacin	>64			●			●
levofloxacin	1-4		●				●
ciprofloxacin	0.5-2		●				●
CI 934	0.25-1	●				●	
Bay Y 3118	0.06-0.25	●				●	
vancomycin	0.12-0.5	●			●		
teicoplanin	0.12-0.5	●			●		
daptomycin	0.25-4		●				●
cotrimoxazole	0.06-0.5	●			●		
chloramphenicol	2-8		●				●
rifampicin	0.04-0.25	●					●
fosfomycin	4-2048			●			●
clindamycin	0.25-4		●				●
tetracycline	0.12-0.5	●					●

at sub MIC levels:



I am a *Listeria monocytogenes*;
but I swear I tell the truth:
I will be as innocent as
Listeria innocua!




Prerequisites for the intracellular activity of an antibiotic

- **Penetration into the cell by diffusion or active transport**
- **Intracellular persistence and eventually accumulation (import higher than export)**
- **Distribution within the cell to the proper compartment where the pathogen resides**
 - a) **cytosol**
 - b) **lysosome**
 - c) **phagocytic vacuole**
 - d) **nucleus**
- **Stability and activity in the particular environmental condition**

Locations of spontaneous expression of the MDR-gen


Duodeum	++
Jejunum	++
Ileum	+++*
Uterus epithelium of pregnant rats	+++
Uterus epithelium of non-pregnant rats	+
Placenta (trophoblasts)	+++
Testis (seminiferous epithelium)	+++
Kidney (cortex)	++
Kidney (medulla)	—
Capillary endothelium in brain	+++

L. monocytogenes log₁₀ cfu / 4x10⁴ eukaryotic cells




Blood-brain-barrier in the parenchyma


- ① capillary endothelium with MDR
- ② tight junctions
- ③ astrocytes
- ④ microglial cells



Blood-CSF-barrier in the choroid plexus

- ① capillary endothelium:
 - no tight junctions
 - partially fenestrated
 - with MDR?
- ② epithelial cells from the choroid plexus (with tight junctions)
- ③ no astrocytes
- ④ no microglia





Reversal of the susceptibility of *L. monocytogenes* by verapamil. KBV-1 cells were incubated without verapamil (\blacktriangledown) and with verapamil (\triangledown). In this experiment, vinblastine was included in the supernatant for the whole incubation time of 24 hours. However, similar results were obtained without vinblastine or with gentamicin, or with a shorter incubation time of 5 hours.

	KBV-1	G185
Erythromycin	+	+
Clarithromycin	+	+
Azithromycin	+	+
Fusidic acid	+	—
Clindamycin	+	—
RP 59500	+	—
Rifampicin	(+)	—
Ciprofloxacin	(+)	—
Ofloxacin	(+)	—
Cotrimoxazole	(+)	—
Doxycycline	(+)	—
Chloramphenicol	—	—
Fosfomycin	—	—
Vancomycin	—	—

Intrazelluläre Verteilung von Antibiotika




Teicoplanin




Aminoglykoside



Makrolide



**Azithromycin;
Chinolone**



Baum

